Cargando…

Association of HLA diversity with the risk of 25 cancers in the UK Biobank

BACKGROUND: The human leukocyte antigen (HLA) is a highly polymorphic region, and HLA diversity may play a role in presenting tumour-associated peptides and inducing immune responses. However, the effect of HLA diversity on cancers has not been fully assessed. We aimed to explore the role of HLA div...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiao-Ling, Wang, Tong-Min, Deng, Chang-Mi, Zhang, Wen-Li, He, Yong-Qiao, Xue, Wen-Qiong, Liao, Ying, Yang, Da-Wei, Zheng, Mei-Qi, Jia, Wei-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189092/
https://www.ncbi.nlm.nih.gov/pubmed/37148584
http://dx.doi.org/10.1016/j.ebiom.2023.104588
_version_ 1785043009841135616
author Wang, Qiao-Ling
Wang, Tong-Min
Deng, Chang-Mi
Zhang, Wen-Li
He, Yong-Qiao
Xue, Wen-Qiong
Liao, Ying
Yang, Da-Wei
Zheng, Mei-Qi
Jia, Wei-Hua
author_facet Wang, Qiao-Ling
Wang, Tong-Min
Deng, Chang-Mi
Zhang, Wen-Li
He, Yong-Qiao
Xue, Wen-Qiong
Liao, Ying
Yang, Da-Wei
Zheng, Mei-Qi
Jia, Wei-Hua
author_sort Wang, Qiao-Ling
collection PubMed
description BACKGROUND: The human leukocyte antigen (HLA) is a highly polymorphic region, and HLA diversity may play a role in presenting tumour-associated peptides and inducing immune responses. However, the effect of HLA diversity on cancers has not been fully assessed. We aimed to explore the role of HLA diversity on cancer development. METHODS: A pan-cancer analysis was performed to evaluate the effect of HLA diversity, measured by HLA heterozygosity and HLA evolutionary divergence (HED), on the susceptibility of 25 cancers in the UK Biobank. FINDINGS: We observed that the diversity of HLA class II locus was associated with a lower risk of lung cancer (OR(hetero) = 0.94, 95% CI = 0.90–0.97, P = 1.29 × 10(−4)) and head and neck cancer (OR(hetero) = 0.91, 95% CI = 0.86–0.96, P = 1.56 × 10(−3)). Besides, a lower risk of non-Hodgkin lymphoma was associated with an increased diversity of HLA class I (OR(hetero) = 0.92, 95% CI = 0.87–0.98, P = 8.38 × 10(−3)) and class II locus (OR(hetero) = 0.89, 95% CI = 0.86–0.92, P = 1.65 × 10(−10)). A lower risk of Hodgkin lymphoma was associated with the HLA class I diversity (OR(hetero) = 0.85, 95% CI = 0.75–0.96, P = 0.011). The protective effect of HLA diversity was mainly observed in pathological subtypes with higher tumour mutation burden, such as lung squamous cell carcinoma (P = 9.39 × 10(−3)) and diffuse large B cell lymphoma (P(class I) = 4.12 × 10(−4); P(class Ⅱ) = 4.71 × 10(−5)), as well as the smoking subgroups of lung cancer (P = 7.45 × 10(−5)) and head and neck cancer (P = 4.55 × 10(−3)). INTERPRETATION: We provided a systematic insight into the effect of HLA diversity on cancers, which might help to understand the etiological role of HLA on cancer development. FUNDING: This study was supported by grants from the 10.13039/501100001809National Natural Science Foundation of China (82273705, 82003520); the 10.13039/501100021171Basic and Applied Basic Research Foundation of Guangdong Province, China (2021B1515420007); the Science and Technology Planning Project of Guangzhou, China (201804020094); Sino-Sweden Joint Research Programme (81861138006); the 10.13039/501100001809National Natural Science Foundation of China (81973131, 81903395, 81803319, 81802708).
format Online
Article
Text
id pubmed-10189092
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101890922023-05-18 Association of HLA diversity with the risk of 25 cancers in the UK Biobank Wang, Qiao-Ling Wang, Tong-Min Deng, Chang-Mi Zhang, Wen-Li He, Yong-Qiao Xue, Wen-Qiong Liao, Ying Yang, Da-Wei Zheng, Mei-Qi Jia, Wei-Hua eBioMedicine Articles BACKGROUND: The human leukocyte antigen (HLA) is a highly polymorphic region, and HLA diversity may play a role in presenting tumour-associated peptides and inducing immune responses. However, the effect of HLA diversity on cancers has not been fully assessed. We aimed to explore the role of HLA diversity on cancer development. METHODS: A pan-cancer analysis was performed to evaluate the effect of HLA diversity, measured by HLA heterozygosity and HLA evolutionary divergence (HED), on the susceptibility of 25 cancers in the UK Biobank. FINDINGS: We observed that the diversity of HLA class II locus was associated with a lower risk of lung cancer (OR(hetero) = 0.94, 95% CI = 0.90–0.97, P = 1.29 × 10(−4)) and head and neck cancer (OR(hetero) = 0.91, 95% CI = 0.86–0.96, P = 1.56 × 10(−3)). Besides, a lower risk of non-Hodgkin lymphoma was associated with an increased diversity of HLA class I (OR(hetero) = 0.92, 95% CI = 0.87–0.98, P = 8.38 × 10(−3)) and class II locus (OR(hetero) = 0.89, 95% CI = 0.86–0.92, P = 1.65 × 10(−10)). A lower risk of Hodgkin lymphoma was associated with the HLA class I diversity (OR(hetero) = 0.85, 95% CI = 0.75–0.96, P = 0.011). The protective effect of HLA diversity was mainly observed in pathological subtypes with higher tumour mutation burden, such as lung squamous cell carcinoma (P = 9.39 × 10(−3)) and diffuse large B cell lymphoma (P(class I) = 4.12 × 10(−4); P(class Ⅱ) = 4.71 × 10(−5)), as well as the smoking subgroups of lung cancer (P = 7.45 × 10(−5)) and head and neck cancer (P = 4.55 × 10(−3)). INTERPRETATION: We provided a systematic insight into the effect of HLA diversity on cancers, which might help to understand the etiological role of HLA on cancer development. FUNDING: This study was supported by grants from the 10.13039/501100001809National Natural Science Foundation of China (82273705, 82003520); the 10.13039/501100021171Basic and Applied Basic Research Foundation of Guangdong Province, China (2021B1515420007); the Science and Technology Planning Project of Guangzhou, China (201804020094); Sino-Sweden Joint Research Programme (81861138006); the 10.13039/501100001809National Natural Science Foundation of China (81973131, 81903395, 81803319, 81802708). Elsevier 2023-05-04 /pmc/articles/PMC10189092/ /pubmed/37148584 http://dx.doi.org/10.1016/j.ebiom.2023.104588 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Wang, Qiao-Ling
Wang, Tong-Min
Deng, Chang-Mi
Zhang, Wen-Li
He, Yong-Qiao
Xue, Wen-Qiong
Liao, Ying
Yang, Da-Wei
Zheng, Mei-Qi
Jia, Wei-Hua
Association of HLA diversity with the risk of 25 cancers in the UK Biobank
title Association of HLA diversity with the risk of 25 cancers in the UK Biobank
title_full Association of HLA diversity with the risk of 25 cancers in the UK Biobank
title_fullStr Association of HLA diversity with the risk of 25 cancers in the UK Biobank
title_full_unstemmed Association of HLA diversity with the risk of 25 cancers in the UK Biobank
title_short Association of HLA diversity with the risk of 25 cancers in the UK Biobank
title_sort association of hla diversity with the risk of 25 cancers in the uk biobank
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189092/
https://www.ncbi.nlm.nih.gov/pubmed/37148584
http://dx.doi.org/10.1016/j.ebiom.2023.104588
work_keys_str_mv AT wangqiaoling associationofhladiversitywiththeriskof25cancersintheukbiobank
AT wangtongmin associationofhladiversitywiththeriskof25cancersintheukbiobank
AT dengchangmi associationofhladiversitywiththeriskof25cancersintheukbiobank
AT zhangwenli associationofhladiversitywiththeriskof25cancersintheukbiobank
AT heyongqiao associationofhladiversitywiththeriskof25cancersintheukbiobank
AT xuewenqiong associationofhladiversitywiththeriskof25cancersintheukbiobank
AT liaoying associationofhladiversitywiththeriskof25cancersintheukbiobank
AT yangdawei associationofhladiversitywiththeriskof25cancersintheukbiobank
AT zhengmeiqi associationofhladiversitywiththeriskof25cancersintheukbiobank
AT jiaweihua associationofhladiversitywiththeriskof25cancersintheukbiobank